[go: up one dir, main page]

EA200700976A1 - Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой - Google Patents

Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой

Info

Publication number
EA200700976A1
EA200700976A1 EA200700976A EA200700976A EA200700976A1 EA 200700976 A1 EA200700976 A1 EA 200700976A1 EA 200700976 A EA200700976 A EA 200700976A EA 200700976 A EA200700976 A EA 200700976A EA 200700976 A1 EA200700976 A1 EA 200700976A1
Authority
EA
Eurasian Patent Office
Prior art keywords
molecule
cell
conjugate
conjugates
inclusion
Prior art date
Application number
EA200700976A
Other languages
English (en)
Inventor
Кристоф Бонни
Дидье Куко
Цзяньхуа Чэнь
Original Assignee
Ксижен С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксижен С.А. filed Critical Ксижен С.А.
Publication of EA200700976A1 publication Critical patent/EA200700976A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описана молекула-конъюгат, включающая по меньшей мере один первый компонент (I), который содержит последовательность-переносчик, и по меньшей мере один второй компонент (II), который содержит по меньшей мере одну молекулу противоопухолевого лекарственного средства или молекулу ингибитора протеазы, где молекула-конъюгат содержит в своем компоненте (I) D-энантиомерные аминокислоты. Кроме того, в заявке описаны фармацевтические композиции, содержащие указанную молекулу-конъюгат, а также применение указанной молекулы-конъюгата для терапевтического лечения. В заявке описаны также способы повышения способности проникать в клетку или растворимости в воде.
EA200700976A 2004-11-12 2005-11-09 Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой EA200700976A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04026934A EP1656951A1 (en) 2004-11-12 2004-11-12 Conjugates with enhanced cell uptake activity
PCT/EP2005/011991 WO2006050930A2 (en) 2004-11-12 2005-11-09 Conjugates with enhanced cell uptake activity

Publications (1)

Publication Number Publication Date
EA200700976A1 true EA200700976A1 (ru) 2007-12-28

Family

ID=34927367

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700976A EA200700976A1 (ru) 2004-11-12 2005-11-09 Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой

Country Status (10)

Country Link
EP (2) EP1656951A1 (ru)
JP (1) JP2008519785A (ru)
CN (1) CN101072589A (ru)
AR (1) AR051765A1 (ru)
AU (1) AU2005303949A1 (ru)
BR (1) BRPI0517843A (ru)
CA (1) CA2585421A1 (ru)
EA (1) EA200700976A1 (ru)
IL (1) IL182760A0 (ru)
WO (1) WO2006050930A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2008082885A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
JP5401457B2 (ja) * 2007-07-26 2014-01-29 ルバンス セラピュティックス インク． 抗菌ペプチド、組成物及びその使用方法
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011069149A2 (en) 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104884078B (zh) * 2012-10-17 2017-06-20 诺和诺德股份有限公司 用于口服肽递送的脂肪酸酰化d‑氨基酸
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2019166347A1 (en) * 2018-02-27 2019-09-06 Lipotrue, S.L. Peptides and compositions for use in cosmetics and medicine
CN108794581B (zh) * 2018-06-26 2021-09-10 江苏大学 一种靶向结合淋巴癌细胞系的特异性d型多肽及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152084A1 (en) * 2003-01-31 2004-08-05 Slattum Paul M. Compounds and processes for single-pot attachment of a label to nucleic acid
ATE251913T1 (de) * 1997-05-21 2003-11-15 Univ Leland Stanford Junior Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
JP2003507438A (ja) * 1999-08-24 2003-02-25 セルゲイト， インコーポレイテッド オリゴアルギニン部分を使用する上皮組織を横切るおよび上皮組織内への薬物送達の増強
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6610820B1 (en) * 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030091640A1 (en) * 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
ES2500921T3 (es) * 2003-04-29 2014-10-01 Sarepta Therapeutics, Inc. Composiciones para potenciar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células

Also Published As

Publication number Publication date
BRPI0517843A (pt) 2008-10-21
CN101072589A (zh) 2007-11-14
JP2008519785A (ja) 2008-06-12
WO2006050930A2 (en) 2006-05-18
AU2005303949A1 (en) 2006-05-18
AR051765A1 (es) 2007-02-07
WO2006050930A3 (en) 2007-04-26
EP1656951A1 (en) 2006-05-17
CA2585421A1 (en) 2006-05-18
EP1809334A2 (en) 2007-07-25
IL182760A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
EA200870164A1 (ru) Лечение вирусного гепатита
EA200870599A1 (ru) Стабильные препараты лаквинимода
SE0001899D0 (sv) New compounds
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
EA200100992A1 (ru) Ингибиторы фермента impdh
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
EA200800514A1 (ru) Замещённые 7-азаиндазолы, содержащие их композиции, способ получения и применения
AR047928A1 (es) Derivados de tetrahidropiridoindol
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
NI200800216A (es) Uso de compuestos peptídicos de tpo y composiciones farmacéuticas en el tratamiento de la anemia
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
EA200400707A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
ATE429435T1 (de) 7h-pyrrolopyrimidinderivate
EA200700067A1 (ru) Фармацевтическая композиция, содержащая производные пиперазина
SE0203817D0 (sv) New composition